目的 研究胃乐新颗粒联合美沙拉嗪肠溶片治疗重度溃疡性结肠炎的临床疗效。方法 选取2017年1月-2018年12月内蒙古医科大学附属医院收治的120例重度溃疡性结肠炎患者为研究对象，将所有患者采用随机数字表法分为对照组和治疗组，每组各60例。对照组患者口服美沙拉嗪肠溶片，4片/次，4次/d；治疗组患者在对照组治疗的基础上口服胃乐新颗粒，1袋/次，3次/d。两组患者接受治疗8周。观察两组的临床疗效，比较两组的临床症状缓解时间、视觉模拟评分法（VAS）评分、疾病活动指数（DAI）评分以及白细胞介素（IL）-6、C反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，对照组和治疗组的总有效率分别为85.00%、96.67%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组腹痛、腹泻、发热和脓血便消失时间显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者VAS评分和DAI评分均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者VAS评分和DAI评分均明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者IL-6、IL-8和TNF-α水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者IL-6、IL-8和TNF-α水平均明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 胃乐新颗粒联合美沙拉嗪肠溶片治疗重度溃疡性结肠炎具有较好的临床疗效，能改善患者临床症状，降低DAI评分和血清炎性因子水平，具有一定的临床推广应用价值。

Objective To study the efficacy of Weilexin Granules combined with Mesalazine Enteric Coated Tablets in treatment of severe ulcerative colitis. Methods Patients (120 cases) with severe ulcerative colitis in the Affiliated Hospital of Inner Mongolia Medical University from January 2017 to December 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Mesalazine Enteric Coated Tablets, 4 tablets/time, four times daily. Patients in the treatment group were po administered with Weilexin Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptoms remission time, VAS scores, DAI scores, the levels of IL-6, IL-8 and TNF-α in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.00% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearance time of abdominal pain, diarrhea, fever and purulent bloody stool in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, VAS scores and DAI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And VAS scores and DAI scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of IL-6, IL-8, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Weilexin Granules combined with Mesalazine Enteric Coated Tablets has clinical curative effect in treatment of severe ulcerative colitis, can improve clinical symptoms, reduce DAI score and serum level of inflammatory factors, which has a certain clinical application value.